statistiche ricercatore

Continente	#
EU - Europa	13.950
NA - Nord America	873
AS - Asia	429
SA - Sud America	78
Continente sconosciuto - Info sul continente non disponibili	53
AF - Africa	13
Totale	15.396

Nazione	#
IT - Italia	13.728
US - Stati Uniti d'America	834
SG - Singapore	158
CN - Cina	128
SE - Svezia	81
BR - Brasile	62
VN - Vietnam	44
BD - Bangladesh	32
DE - Germania	25
UA - Ucraina	25
CA - Canada	23
FI - Finlandia	22
FR - Francia	19
GB - Regno Unito	15
HK - Hong Kong	14
IN - India	11
IL - Israele	6
AR - Argentina	5
ES - Italia	5
IQ - Iraq	5
RU - Federazione Russa	5
AT - Austria	4
BE - Belgio	4
JP - Giappone	4
PL - Polonia	4
TR - Turchia	4
ZA - Sudafrica	4
CO - Colombia	3
EC - Ecuador	3
ID - Indonesia	3
MX - Messico	3
SA - Arabia Saudita	3
AE - Emirati Arabi Uniti	2
AZ - Azerbaigian	2
CR - Costa Rica	2
GT - Guatemala	2
KE - Kenya	2
KR - Corea	2
LV - Lettonia	2
MA - Marocco	2
NL - Olanda	2
PK - Pakistan	2
PR - Porto Rico	2
RO - Romania	2
SV - El Salvador	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
VE - Venezuela	2
AL - Albania	1
CH - Svizzera	1
CI - Costa d'Avorio	1
CL - Cile	1
CW - ???statistics.table.value.countryCode.CW???	1
DK - Danimarca	1
DO - Repubblica Dominicana	1
EE - Estonia	1
EG - Egitto	1
GA - Gabon	1
HN - Honduras	1
IR - Iran	1
JM - Giamaica	1
KG - Kirghizistan	1
KH - Cambogia	1
LB - Libano	1
LU - Lussemburgo	1
ML - Mali	1
MT - Malta	1
MY - Malesia	1
OM - Oman	1
PH - Filippine	1
PS - Palestinian Territory	1
PT - Portogallo	1
TN - Tunisia	1
UZ - Uzbekistan	1
Totale	15.344

Nome	#
Thalassemia major between liver and heart: Where we are now	4.122
Current growth patterns in children and adolescents with thalassemia major	3.027
Deferasirox and children: From clinical trials to the real world	2.506
Thalassemia major: who is afraid of serum ferritin below 500 μg/l?	2.051
Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload	1.360
Impact of the direct-acting antiviral agents (DAAs) on chronic hepatitis C in Sardinian patients with transfusion-dependent Thalassemia major	853
Safety and Efficacy of the New Combination Iron Chelation Regimens in Patients with Transfusion-Dependent Thalassemia and Severe Iron Overload	553
Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice	325
Unplanned pregnancy in women with beta-thalassaemia treated with luspatercept	239
Luspatercept for Transfusion-Dependent Beta-Thalassemia: Real-World Experience in a Large Cohort of Patients From Italy	171
Real-world evidence supports the safety and efficacy profile of luspatercept in clinically complex and heavily iron-overloaded patients	99
Pregnancy and childbirth in women with thalassemia: past and present	90
Totale	15.396

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	510	0	0	0	0	85	54	24	68	83	102	55	39
2022/2023	1.124	78	220	239	89	70	62	38	100	40	66	80	42
2023/2024	1.003	48	32	26	57	74	164	173	79	57	86	93	114
2024/2025	4.232	1.617	974	794	285	111	177	168	14	31	21	26	14
2025/2026	930	60	48	80	76	67	101	122	76	80	96	61	63
2026/2027	235	11	42	53	113	16	0	0	0	0	0	0	0
Totale													15.396

UNICA IRIS Institutional Research Information System